Patients with a rare, deadly disease that mostly affects young women felt a dramatic reduction in breathlessness using an approved drug, according to study results published online in The Journal of Heart and Lung Transplantation. The treatment, continuous intravenous (IV) treprostinil, has already been approved by the U.S. Food and Drug Administration for the treatment of pulmonary arterial hypertension (PAH) based on its similarity to an approved treatment delivered subcutaneously (directly into the skin)...
More...
More...